WO1992018109A1 - Preparation solide rapidement soluble - Google Patents
Preparation solide rapidement soluble Download PDFInfo
- Publication number
- WO1992018109A1 WO1992018109A1 PCT/JP1992/000469 JP9200469W WO9218109A1 WO 1992018109 A1 WO1992018109 A1 WO 1992018109A1 JP 9200469 W JP9200469 W JP 9200469W WO 9218109 A1 WO9218109 A1 WO 9218109A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- solid preparation
- hydrochloride
- dissolving
- enteric base
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
Definitions
- the present invention relates to a pH-independent fast-dissolving solid preparation containing, as a main ingredient, a drug whose solubility rapidly decreases with an increase in pH.
- Fast-dissolving solid preparations are designed to allow the blood concentration of the drug to reach the effective blood concentration range quickly after oral administration, and to expect the drug to be effective immediately. Therefore, when designing a fast-dissolving solid formulation, the disintegration of the solid drug itself, the dissolution property of the drug, and the bioavailability of the drug (pior-a-birrupity) become problems.
- drugs whose solubility decreases rapidly with increasing pH generally have poorer gastrointestinal absorption than that of the intestinal tract, even though they have better disintegration and solubility in gastric juices Therefore, there is a problem that the biological availability of the administered drug is reduced. In addition, there is a problem that such drugs cannot be expected to have the desired drug efficacy even in patients with anoxia or hypogastric acidosis.
- a solid solution (also referred to as solid dispersion) in which the drug is dispersed in a substantially amorphous form in an inert carrier such as polyvinylpyrrolidone is used.
- an inert carrier such as polyvinylpyrrolidone
- a fast-dissolving product with improved absorption of diphedipine a poorly soluble drug.
- a poorly soluble drug is mixed with a base such as polybulpyrrolidone or a mixture thereof with a surfactant, and the mixture is mixed with a fluidized bed. It has been shown that a compression molded product using a granulated product by the granulation method is excellent in terms of easy disintegration, easy absorption, and rapid solubility. Etc. are used.
- N- (1-benzyl-2-methylbi-lysine-13-yl) -15-chloro a drug that becomes insoluble with increasing pH.
- Mouth 2-Methoxy-4-methylaminobenzamide and its salts have been studied for the purpose of developing a fast-dissolving solid preparation that is not dependent on PH.
- a solid preparation using particles obtained by coating small particulate nuclei as a solid solution with an enteric base material has excellent dissolution properties even under low pH conditions, and dissolution properties even when PH is increased. And that the overall bioavailability is much better, The present invention has been completed.
- the present invention relates to a solid preparation containing particles composed of a small particle nucleus and a drug layer coated on the small particle nucleus, wherein the drug layer comprises (1) an enteric base and
- an enteric base generally suppresses the release of a drug under low pH conditions, and is used as a base for releasing a drug for the first time at a pH in the intestinal tract.
- a poorly pH-dependent poorly soluble drug and a certain amount of an enteric base makes it possible to obtain a fast-dissolving drug that does not depend on pH. Therefore, this pH-dependent poorly soluble drug, when combined with a specific amount of enteric base, has the property of eluting from the composition with the enteric base under low pH conditions. It is a thing.
- Chilaminonovenzamide is commonly called emonapride, and its hydrochloride is called emonapride hydrochloride.
- Emonapride and its salts were synthesized for the first time by researchers of the applicant company and are useful as therapeutic agents for psychiatric disorders such as schizophrenia (Japanese Patent Publication No. 55-165578). Gazette). For such indications: the development of a fast-dissolving formulation was desired, Sodium and its salts rapidly decrease in solubility at pH 4 and higher, and improvements have been desired.
- the drug used in the present invention is a drug whose solubility sharply decreases with an increase in pH, but is a solid containing particles obtained by coating small particulate nuclei as a solid solution with an enteric base.
- Any drug can be used as long as it is excellent in dissolution from the formulation without depending on PH and has a particularly high bioavailability, and is not limited to emonapride or its salt.
- examples of such drugs include dicardipine hydrochloride, amosuralol hydrochloride, nosporin hydrochloride, propafenone hydrochloride, quinine hydrochloride, dipyridamole, josamicin, dileparol hydrochloride, labetalol hydrochloride and the like.
- the drug is formulated as a solid dosage unit formulation in an amount that produces the desired drug effect, but usually 0.5 to 10.0% (wZw), especially small It is advantageous to mix 3.0 to 5.0% [wZw] to obtain a compressed solid preparation.
- the small particulate nuclei used in the present invention may be any as long as they can cover the surface of a solid solution and do not impair the object of the present invention.
- examples thereof include calcium hydrogen phosphate, sucrose, lactose, starch, and crystalline cellulose. Good.
- the amount used will vary depending on the drug and the base used, but for example, it is preferably used within the range of 5 to 50% (wZw) based on the whole preparation.
- the enteric base used in the present invention may be any enteric base which is insoluble in water at low pH or in water and dissolves under high pH.
- Dependent enteric bases are preferred.
- Such an enteric base is insoluble in water and soluble at pH 5.0 or higher Hydroxy, propyl propyl cellulose cellulose phthalate, methacrylic acid / methyl methacrylate copolymer, cellulose acetate phthalate, hydroxypropyl propyl methyl cellulose cellulose acetate Succinate, calpoxymethylethyl cellulose, and the like.
- enteric bases can be used in combination of two or more, but usually achieve the desired effect with a single product.
- the amount of enteric base used is preferably 5 times or less, especially 2 times or less, relative to the drug, and 2 to 20% C w / w is advantageous for the whole drug product. .
- Tablets are suitable as the solid preparation of the present invention, but any solid preparation that can be orally administered may be used.
- the fast-dissolving preparation of the present invention is obtained by coating a solution obtained by dissolving a drug and an enteric base on the surface of a small particulate nucleus, granulating and drying the obtained particles, and then using a suitable excipient or disintegrant. It is manufactured by adding a lubricant and other additives into a solid preparation.
- Solvents that dissolve the drug and the enteric base include methanol and ethanol.
- ketones such as low-boiling alcohols such as alcohol, acetone and methylethyl ketone, halogenated hydrocarbon-based organic solvents such as dichloromethane and dichloroethane, and mixed solvents thereof.
- the coating is not limited to the fluidized-bed granulation method, but may be any method capable of forming a solid solution by coating, such as a centrifugal fluidized coating method or a fluidized-bed coating method.
- the granulation may be carried out simultaneously with or subsequent to coating with a coating granulation dryer, or a general wet granulation method using a dried coating may be used. Drying, cold enough to remove the organic solvent and binder solution, is carried out in several hours, for example 4 0 ° C is preferred c
- the additives to be added to the fast-dissolving preparation of the present invention are appropriately selected according to the type of the solid preparation, and the amount is set.
- excipients used include, for example, starch, lactose, crystalline cellulose, mannite, sucrose, calcium sulfate, calcium lactate, synthetic aluminum silicate, calcium hydrogen phosphate, silicic anhydride, aluminum metasilicate. Magnesium acid and the like.
- Disintegrants include starch, crystalline cellulose, calcium carboxymethylcellulose, etc.
- lubricants include magnesium stearate, talc, hydrogenated vegetable oils, etc.
- binders such as starch and hydroxy. Cyprovir cellulose and the like are advantageously used. Flavoring agents and flavoring agents may be added, if necessary, or sugar coating may be applied according to the usual methods.
- Tableting may be either direct compression or wet compression.
- the present invention is characterized by the fact that it has been able to provide an easily absorbable solid preparation excellent in fast solubility, pH-independent dissolution, and bioavailability of a PH-dependent drug whose solubility decreases with an increase in pH.
- it has a remarkable effect that is completely unexpected from known techniques.
- Comparative Example 2 30 g of emonabride hydrochloride was pulverized with a sample mill. Combine lactose (700 g), carboxymethylcellulose calcium (100 g), corn starch (335.5 g), and calcium stearate (12 g). Hereinafter, these 3 mg tablets are referred to as tablet A.
- the test was performed at 100 revolutions per minute according to the Japanese Pharmacopoeia, Dissolution Test Method 2 (paddle method).
- 900 ml of JP 1 solution (pH 1.2) and JP 2 solution (pH 6.8) were used in 900 ml.
- the first solution is pH 2.0 to 5.0 for acetate buffer (S 0 rensen buffer), and pH 6.0 to 7.6 is phosphate buffer (C 1 ark Lubs buffer). ) was used.
- pH 6.8 the Japanese Pharmacopoeia second solution was used.]
- the eluate was continuously filtered through a two-pore pore membrane (pore size 0.2 or 0.6 / m).
- Emonapride hydrochloride (0.05 to 5 g) was added to 10 ml of test solutions at various pHs, shaken at 37 ° C for 1 hour, and then treated with Nikulipo membrane (pore size: 0. 6 ⁇ m). An aliquot of the filtrate was taken and diluted with an acetate buffer at pH 3.0 to obtain a sample solution.
- emonabride hydrochloride was precisely weighed and dissolved in methanol to make exactly 100 ml. Measure exactly 1 ml of this solution, and set the pH to 3. An acetic acid buffer solution of 0 was added to make exactly 100 ml, which was used as a standard solution. The absorbance at 313 nm of the sample solution and the standard solution was measured by the absorbance measurement method to determine the solubility.
- ⁇ ⁇ 1 22 is JP 1st solution
- ⁇ ⁇ 2.0-5.0 is drunk acid buffer (S-5 rensen buffer)
- pH 6.0-7 .6 used a phosphate buffer [Clark Lubs buffer].
- pH ⁇ .8 the Japanese Pharmacopoeia second liquid was used.
- the solubility of the drug substance of emonapride hydrochloride is 5000 ⁇ g Zi1 or more up to ⁇ ⁇ 4, but decreases rapidly when pH4 is exceeded. . On 8 J3 ⁇ 4, it is less than 10 ⁇ gZm1 and depends on pH.
- Figure 3 shows the dissolution behavior of nemonapride hydrochloride from emonapride hydrochloride 3 mg sugar-coated tablet (hereinafter referred to as tablet B), which is a tablet containing solid solution-coated particles obtained in Example 1. Show.
- Cma x is t AUC shown by the average of the respective values of the unchanged drug concentration in each plasma was calculated for 0-8 hours Ri by the trapezoidal method.
- FIG. 5 shows the average unchanged plasma concentration of plasma when tablets A and B were orally administered to dogs.
- Tablet B was found to be a formulation with little pH dependence and rapid dissolution, with greatly improved bioavailability.
- Figure 1 shows the solubility of emonapride hydrochloride in various test solutions at various pH values. Shows the resolution (37).
- FIG. 2 shows the dissolution behavior of emonapride hydrochloride from 3 mg of Tablet A in various ⁇ H test solutions.
- FIG. 3 shows the dissolution behavior of emonapride hydrochloride from 3 mg of Tablet B in various ⁇ H test solutions.
- FIG. 4 shows the dissolution behavior of emonabride hydrochloride from tablets C l O mg in various ⁇ H test solutions.
- Figure 5 shows the mean unchanged plasma concentration of plasma when emonapride hydrochloride tablets were orally administered to dogs.
- Emonapride hydrochloride 570 g, hydroxypropyl methylcell monoester phthalate 22 0 8 24 1, 7110 g, macrogol 400 5 70 g in solvent (metanol 1) , 140 g, methylene chloride 21 ⁇ 60 g). Furthermore, after suspending 570 g of magnesium metasilicate aluminate, it is sprayed on 5,700 g of anhydrous calcium hydrogen phosphate using a fluidized bed granulator (FLO-5) to obtain granules.
- FLO-5 fluidized bed granulator
- FLO-5 fluidized bed granulator
- the granulated product was mixed with 4,440 g of calcium hydrogen anhydride, 2,400 g of crystalline cellulose, 240 g of carboxymethyl cellulose calcium, and 120 g of calcium stearate, and tableted. And then sugar-coated to obtain sugar-coated tablets,
Landscapes
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/137,054 US5624687A (en) | 1991-04-15 | 1992-04-14 | Quick-dissolution solid preparation |
KR1019930703133A KR0179343B1 (ko) | 1991-04-15 | 1992-04-14 | 속용성 고형 제제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3/109896 | 1991-04-15 | ||
JP10989691 | 1991-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992018109A1 true WO1992018109A1 (fr) | 1992-10-29 |
Family
ID=14521910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1992/000469 WO1992018109A1 (fr) | 1991-04-15 | 1992-04-14 | Preparation solide rapidement soluble |
Country Status (8)
Country | Link |
---|---|
US (1) | US5624687A (ja) |
EP (1) | EP0580862A4 (ja) |
KR (1) | KR0179343B1 (ja) |
AU (1) | AU1644092A (ja) |
CA (1) | CA2108374A1 (ja) |
HU (1) | HUT67388A (ja) |
TW (1) | TW212139B (ja) |
WO (1) | WO1992018109A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000229888A (ja) * | 1999-02-10 | 2000-08-22 | Pfizer Prod Inc | マトリックス制御放出デバイス |
JP2003521686A (ja) * | 2000-01-28 | 2003-07-15 | ピオン,インコーポレイテッド | 溶解度−pHプロフィールの測定 |
WO2006080778A1 (en) * | 2005-01-25 | 2006-08-03 | Gl Pharmtech Corp. | Solid dispersion comprising tacrolimus and enteric-coated macromolecule |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040018236A1 (en) * | 1995-05-08 | 2004-01-29 | Robert Gurny | Nanoparticles for oral administration of pharmaceutical agents of low solubility |
US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
US6974590B2 (en) * | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
US20030118645A1 (en) * | 1998-04-29 | 2003-06-26 | Pather S. Indiran | Pharmaceutical compositions for rectal and vaginal administration |
US6141260A (en) | 1998-08-27 | 2000-10-31 | Micron Technology, Inc. | Single electron resistor memory device and method for use thereof |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
GB0012448D0 (en) | 2000-05-24 | 2000-07-12 | Astrazeneca Ab | New process |
GB0104752D0 (en) * | 2001-02-27 | 2001-04-18 | Astrazeneca Ab | Pharmaceutical compositions |
US20030017175A1 (en) * | 2001-07-05 | 2003-01-23 | R.T. Alamo Ventures I, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
GB0217056D0 (en) * | 2002-07-23 | 2002-08-28 | Ass Octel | Use |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
WO2005065319A2 (en) * | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
AU2004311879B2 (en) * | 2003-12-31 | 2010-08-05 | Cima Labs Inc. | Effervescent oral opiate dosage form |
US7858121B2 (en) * | 2003-12-31 | 2010-12-28 | Cima Labs, Inc. | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
US8861813B2 (en) * | 2008-03-13 | 2014-10-14 | Mallinckrodt Llc | Multi-function, foot-activated controller for imaging system |
US11304960B2 (en) * | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
JP2020503269A (ja) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | 経口ウンデカン酸テストステロン療法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5649314A (en) * | 1979-07-05 | 1981-05-02 | Yamanouchi Pharmaceut Co Ltd | Lasting pharmaceutical composition having prolonged action and its preparation |
JPS58116414A (ja) * | 1981-12-23 | 1983-07-11 | Yamanouchi Pharmaceut Co Ltd | ニカルジピン持続性製剤用球形顆粒およびその製造法 |
JPS5840529B2 (ja) * | 1975-09-29 | 1983-09-06 | 明治製菓株式会社 | ケイコウヨウセイザイノセイホウ |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE426548B (sv) * | 1978-12-05 | 1983-01-31 | Haessle Ab | Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer |
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
JP2528706B2 (ja) * | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
IL92343A0 (en) * | 1988-12-20 | 1990-07-26 | Gist Brocades Nv | Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them |
DE3900811A1 (de) * | 1989-01-13 | 1990-07-19 | Kali Chemie Pharma Gmbh | Neue arzneiform |
JPH0729926B2 (ja) * | 1989-07-25 | 1995-04-05 | 大塚製薬株式会社 | 易吸収性製剤用組成物 |
ATE114472T1 (de) * | 1989-09-21 | 1994-12-15 | American Cyanamid Co | System des typs ''einmal täglich'' zur gepulsten minocyclinabgabe. |
US5223268A (en) * | 1991-05-16 | 1993-06-29 | Sterling Drug, Inc. | Low solubility drug-coated bead compositions |
US5213811A (en) * | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
-
1992
- 1992-04-10 TW TW081102791A patent/TW212139B/zh active
- 1992-04-14 WO PCT/JP1992/000469 patent/WO1992018109A1/ja not_active Application Discontinuation
- 1992-04-14 AU AU16440/92A patent/AU1644092A/en not_active Abandoned
- 1992-04-14 EP EP92908470A patent/EP0580862A4/en not_active Ceased
- 1992-04-14 CA CA002108374A patent/CA2108374A1/en not_active Abandoned
- 1992-04-14 KR KR1019930703133A patent/KR0179343B1/ko not_active IP Right Cessation
- 1992-04-14 US US08/137,054 patent/US5624687A/en not_active Expired - Fee Related
- 1992-04-14 HU HU9302927A patent/HUT67388A/hu unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5840529B2 (ja) * | 1975-09-29 | 1983-09-06 | 明治製菓株式会社 | ケイコウヨウセイザイノセイホウ |
JPS5649314A (en) * | 1979-07-05 | 1981-05-02 | Yamanouchi Pharmaceut Co Ltd | Lasting pharmaceutical composition having prolonged action and its preparation |
JPS58116414A (ja) * | 1981-12-23 | 1983-07-11 | Yamanouchi Pharmaceut Co Ltd | ニカルジピン持続性製剤用球形顆粒およびその製造法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0580862A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000229888A (ja) * | 1999-02-10 | 2000-08-22 | Pfizer Prod Inc | マトリックス制御放出デバイス |
JP2005320354A (ja) * | 1999-02-10 | 2005-11-17 | Pfizer Prod Inc | マトリックス制御放出デバイス |
JP4694298B2 (ja) * | 1999-02-10 | 2011-06-08 | ベンド・リサーチ・インコーポレーテッド | マトリックス制御放出デバイス |
JP2003521686A (ja) * | 2000-01-28 | 2003-07-15 | ピオン,インコーポレイテッド | 溶解度−pHプロフィールの測定 |
WO2006080778A1 (en) * | 2005-01-25 | 2006-08-03 | Gl Pharmtech Corp. | Solid dispersion comprising tacrolimus and enteric-coated macromolecule |
Also Published As
Publication number | Publication date |
---|---|
HUT67388A (en) | 1995-04-28 |
US5624687A (en) | 1997-04-29 |
TW212139B (ja) | 1993-09-01 |
KR0179343B1 (ko) | 1999-03-20 |
HU9302927D0 (en) | 1993-12-28 |
CA2108374A1 (en) | 1992-10-16 |
EP0580862A1 (en) | 1994-02-02 |
AU1644092A (en) | 1992-11-17 |
EP0580862A4 (en) | 1995-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1992018109A1 (fr) | Preparation solide rapidement soluble | |
JP6574417B2 (ja) | 非晶質ダパグリフロジンを含有する製剤 | |
JP6666254B2 (ja) | アンドロゲン受容体アンタゴニストの固体医薬組成物 | |
JP3696087B2 (ja) | イトラコナゾール(itraconazole)経口用製剤及びその製造方法 | |
JPH0249728A (ja) | ジヒドロピリジン化合物の製剤組成物 | |
JPH07145052A (ja) | 良好な溶解特性を有する医薬組成物 | |
RU2436576C2 (ru) | Пероральная композиция, содержащая 3-{5-[4-(циклопентилокси)-2-гидроксибензоил]-2-[(3-гидрокси-1,2-бензизоксазол-6-ил)метокси]фенил}пропионовую кислоту или ее соль | |
JPH04210919A (ja) | ピモベンダン経口投与製剤 | |
KR20100131477A (ko) | 음식 없이 지프라시돈을 투여하기 위한 방법, 투여형 및 키트 | |
EP2068835A2 (en) | Imatinib compositions | |
JP2009538912A (ja) | インターロイキン−1β変換酵素阻害剤の経口制御放出剤形 | |
US6727243B1 (en) | Compositions comprising cefuroxime axetil | |
Yamashita et al. | Expedited tablet formulation development of a highly soluble carbamazepine cocrystal enabled by precipitation inhibition in diffusion layer | |
EP0571973B1 (en) | Slow-release sodium valproate tablets | |
AU757547B2 (en) | Novel compositions of eprosartan | |
JP2004131393A (ja) | 易溶出性製剤 | |
PT2165702E (pt) | Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida | |
KR101008540B1 (ko) | 용출률 향상과 부작용 발현이 최소화된 실로스타졸 서방정 | |
JP2009510034A (ja) | 苦味活性成分の口腔内崩壊錠 | |
JPH07112932A (ja) | 徐放性医薬製剤 | |
WO2019007317A1 (zh) | 一种药物组合物及其制备方法 | |
JP3006883B2 (ja) | 速溶性固形製剤 | |
KR0172134B1 (ko) | 고형 제제 | |
RU2816913C2 (ru) | Твердая дисперсия и способ ее получения | |
Liu et al. | Polymer‐coated microparticles for the sustained release of nitrofurantoin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KR LK LU MG MN MW NL NO PL RO RU SD SE US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2108374 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019930703133 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992908470 Country of ref document: EP Ref document number: 08137054 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992908470 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWR | Wipo information: refused in national office |
Ref document number: 1992908470 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992908470 Country of ref document: EP |